Stocks
Neurocrine Biosciences (NBIX) EV/EBITDA US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| EV/EBITDA | ? | 56.4 | 40.5 | 29.5 | 20.5 | 19.6 | 16.8 | ||
| Changes by years, y/y, % | +122% | -28% | -27% | -31% | -4% | -5.1% | |||
Neurocrine Biosciences. EV/EBITDA
Neurocrine Biosciences. EV/EBITDA, changes, %
Neurocrine Biosciences (NBIX) EV/EBITDA US GAAP (quarter values) |
||||||||
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | LTM ? | |||
| EV/EBITDA | ? | 18.8 | 21.4 | 20.7 | 18.1 | 14.0 | 16.8 | |
| Changes by years, y/y, % | -15% | +1% | +28% | -11% | -26% | |||
| Changes by quarters, q/q, % | -8% | +14% | -3% | -12% | -23% | |||
